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Abstract:  
Objective: The objective of this study was to evaluate vaccination 
coverage retrospectively from birth to 14 year-old children for the period of 
years 2012-2016, considering also some factors that influence vaccine uptake. 
Methods: Immunization coverage is the proportion of the number of children 
vaccinated and those  scheduled for vaccination. In this study, this value was 
calculated referring to the national immunization schedule against diphtheria, 
tetanus, pertussis, Hepatitis B, mumps, rubella and measles for the district of 
Korça. Results: Vaccine coverage levels referring to this district for MMR 
vaccine resulted to be 97.4% and for Hepatitis B vaccine resulted to be always 
above 98%. As for the third dose of the DTP-HepB-Hib vaccine, the average 
value was found to be 96%. Conclusion: The 2015-2016 period showed an 
increase in vaccine coverage values for the DTP vaccine. Also, during this 
period there was a noticeable drop in the coverage levels for the third booster 
dose of the penta-valent vaccine (DTP-Hep.B-Hib). Vaccine coverage values 
analyzed for the year 2016 showed a non-optimal continuity regarding to the 
fourth booster dose of TT/ Td vaccine. 
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Introduction 
Vaccination against infectious agents is one of the most widespread 
and consolidated approaches to the primary prevention of diseases in the 
population of the world. Vaccines are generally safe, and serious adverse 
reactions are uncommon (WHO, 2013). Routine immunization programmes 
provides protection from a number of infectious diseases that previously 
caused millions of deaths each year (WHO, 2019), (Plotkin, 2014). 
In the present time, vaccines against diseases such as HIV, malaria, 
cancer, are under different stages of clinical trials (Delany, Rappuoli & De 
Gregorio, 2014). 
In Albania, the national immunization programme has undergone 
several stages, during which new antigens have been added;  the origin of 
antigens, the forms of combination or their administration have changed too. 
Immunization coverage rate is an index of the vaccination programme 
performance and provides an overview of immunity in the population 
(Wallace, Ryman & Dietz, 2014). This indicator does not give information 
about the level of protection (Andre et al, 2008). The goal of this public health 
intervention is to reduce the incidence of vaccine-preventable diseases by 
administration of potent vaccines administered at the appropriate ages 
(Grrenwood, 2014; Katz, Wild, Elmore & Lucan, 2013).   
A series of specifically modified antigens with diverse potences, that 
can stimulate different levels of active immunity in an individual have been 
produced using various technologies (Pojani, Nelaj & Ylli, 2017). In the recent 
years a trend toward the use of combined vaccines is noticed with the purpose 
to increase the practicality of application achieving high coverage for more 
than one antigen at the same time and minimizing logistical problems 
(Lahariya, 2015). 
National coverage for routine child immunization with DTP vaccine 
exceeds the level 95% in 2015 and 2016 as a result of using the combined 
DTP-HepB-Hib vaccine (Pojani, Nelaj, 2016). Immunization coverage of the 
value 98% was estimated for Diphtheria-tetanus-pertussis (Pojani, 2017). 
In this study, the vaccine coverage has been analyzed precisely for the 
region of Korca as it represents a city that lies in the southeast of Albania with 
a large territorial area, about 1800 km2 and also with a strategic geographic 
position bordered by two important countries in the Balkans.  
 
Subjects and Methods 
This study intended to demonstrate how a very important indicator 
such as the vaccination coverage can affect and describe the immunization 
situation in a particular district like Korca in the period from 2012 up to 2016. 
Immunization coverage is usually assessed on the basis of the percentage of 
children who have received a certain number of recommended vaccine dose 
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(WHO, 2018). The vaccination coverage is expressed as a proportion of the 
number of children vaccinated and the number of children scheduled for 
vaccination (WHO, 2009) referring to vaccines within the routine 
immunization schedule (e.g. diphtheria, tetanus, pertussis, Hepatitis B, DTP-
Hep.B-Hib, MMR). The data needed to evaluate and analyze the levels of 
vaccination coverage for this city were provided by the Regional Public Health 
Directorate, Epidemiology Sector in Korca. 
The data analysis was performed using SPSS version 21.0. 
Immunization coverage was calculated by the formula below. 
𝐼𝑚𝑚𝑢𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 (%)
=
𝑇ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 𝑠𝑐ℎ𝑒𝑑𝑢𝑙𝑒𝑑 𝑓𝑜𝑟 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛
 𝑥 100 
 
Results 
Children of one year old age undergo a MMR vaccine followed by a 
booster dose which is given at the age of 5. Vaccination coverage for the first 
dose of MMR vaccine for the year 2016 is calculated to be 96.4% and 99% 
relative to the booster dose. For the first booster dose of DTP vaccine, year 
2015 showed a high coverage value (98.7%) in comparison to other years 
considered in the study. As for the DT and Td vaccine a high coverage value 
(98.6 and 99.3% respectively) was calculated in 2013. Table 1 presents the 
analysis of the vaccine coverage value for each year.  
Vaccine  
type 
         
Year 
Hep.B-0 DTP-
Hep.B-
Hib (1) 
 
DTP-
Hep.B-Hib 
(2) 
 
DTP-
Hep.B-
Hib (3) 
 
DTP DT Td MMR MMR 1-
Booster  
2012 99.6 99.3 98.7 98.2 98.4 98.6 98.8 99.1 99.3 
2013 98.9 98.2 98.3 97.0 98.4 98.6 99.3 98.1 95.7 
2014 99.1 98.1 98.7 95.6 96.3 96.9 96.7 95.7 95.9 
2015 99.7 99.7 98.5 99.4 98.7 96.9 95.6 96.5 97.0 
2016 99.7 97.6 99.4 90.0 97.5 97.4 97,7 96.4 99.0 
Average 
value (%) 
99.4 98.5 98.7 96.0 97.8 97.7 97.6 97.2 97.4 
95% CI: 99.0-
99.7 
97.8- 
99.3 
98.3-
99.0 
92.8-
99.2 
96.9- 
98.7 
96.9- 
98.4 
96.3- 
98.9 
95.9-
98.4 
95.9-98.8 
Table 1: Immunization coverage (%) for the period 2012-2016 in Korça region 
 
Table 2 presents vaccine coverage values for vaccines applied during the first 
24 months of child’s life. 
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Vaccine  
type 
         
Year 
Hep.B-
0 
DTP-
Hep.B-
Hib (1) 
2nd 
month 
DTP-
Hep.B-
Hib (2) 
4th 
month 
DTP-
Hep.B-
Hib (3) 
6th 
month 
MMR DTP 
2012 99.6 99.3 98.7 98.2 99.1 98.4 
2013 98.9 98.2 98.3 97.0 98.1 98.4 
2014 99.1 98.1 98.7 95.6 95.7 96.3 
2015 99.7 99.7 98.5 99.4 96.5 98.7 
2016 99.7 97.6 99.4 90.0 96.4 97.5 
Average 
value (%) 
99.4 98.5 98.7 96.0 97.2 97.8 
95% CI:  
99.0-99.7 
 
97.8- 
99.3 
 
98.3-
99.0 
 
92.8-99.2 
 
95.9-98.4 
 
97.0- 98.7 
 
Table 2: The coverage for the vaccines applied within the first 24 months of life for the 
Korça Region 
 
Based on the evidences and calculations, the average value of vaccine 
coverage for Hepatitis B vaccine in the period 2012-2016, resulted to be 99.4% 
(95% CI 99.0-99.7%). As for the DTP-Hep.B-Hib vaccine the coverage values 
were calculated 98%. 
Vaccine coverage value for DTP-Hep.B-Hib3 vaccine (since 2009 the 
Hepatitis B component was included in the combined penta-valent DTP-
Hep.B-Hib vaccine), during 2016 was found to be below 95% (95% CI: 92.8-
99.2). As for the trivalent vaccine MMR, 2012 and 2013 cohorts represented 
high levels of vaccine coverage with a value of 97.2% (95% CI: 95.9- 98.4%). 
 
Immunization coverage: HepB-0 (the first dose immediately administered 
at birth) 
Referring to the first dose of Hepatitis B vaccine, administered to all 
neonates at birth or immediately afterwards, as presented in Chart 1, the annual 
average values of vaccine coverage for the period 2012-2016 resulted to be 
above 98%, especially for 2015 and 2016 cohorts where the value calculated 
was 99.7%. 
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Chart 1: Immunization coverage for the (HepB-0) dose immediately administered to 
neonates at birth; period 2012-2016 in Korça Region. 
 
Immunization coverage in childhood (5-6 year old children) 
Considering the trivalent vaccine MMR, specially the first booster 
dose applied to children at 5, for the same period (2012-2016), the average 
values of vaccine coverage resulted to be 97.4% (95% CI: 95.8- 98.8%), 
according to the Table 3 below. 
 
Vaccine  type                                                  
 
Year 
MMR 1° DT 
2012 99.3 98.6 
2013 95.7 98.6 
2014 95.9 96.9 
2015 97.0 96.9 
2016 99.0 97.4 
Average value (%) 97.4 97.7  
95% CI: 95.8- 98.8 96.9- 98.4 
 
Table 3: Vaccine coverage for some vaccines applied to 5-6 year old children in  Korça 
District 
 
Immunization coverage for vaccines applied in adolescence (14-18 years 
old) 
Immunization coverage levels for the reinforcing dose of combined 
tetanus/diphtheria vaccine appeared to be higher than the values considered as 
optimal, in fact an average value of 97.6% (95% CI: 96.3- 98.9%) was 
observed. On the other hand, regarding the fourth booster dose of TT/Td 
vaccine, the immunization coverage levels for 2014 and 2016 never reached 
the recommended value (95%) and in fact it reached an average of 91.7% 
(95% CI: 87.8- 95.5%). 
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Discussion 
Immunization schedule in Albania has been improved gradually by 
adding new vaccines or new vaccine components such as rubella component 
(generating the MR vaccine) introduced in 2000 and mumps component in 
2005, generating the MMR vaccine in current use by the national 
immunization calendar. 
Referring to the vaccination programme, all children should get four 
doses of DTP vaccine, one dose at each of the following ages: the first booster 
(DTP) at the age of  2, the second booster (DT) at the age of 6 years, followed 
by a third and a fourth booster dose (Td) which are applied at the age of 14 
and 18. 
Based on the evidences, Hepatitis B vaccine attains sustainable levels even in 
national extend. As for the coverage values of vaccines applied during the first 
24 months of child’s life, Chart 2 clearly shows high levels of immunization 
coverage reflected by this district for the DTP-Hep.B-Hib vaccine. 
 
Immunization coverage: HepB-0 
Hepatitis B is a life-threatening liver infection caused by the hepatitis 
B virus (HBV). It is a major global health problem (Chang, Chen, 2015). The 
vaccine against hepatitis B is 95% effective in preventing infection and the 
development of chronic disease and liver cancer due to Hepatitis B (Bhat, 
Ghali, Deschenes & Wong 2014). It is extremely necessary that all neonates 
should get the first dose of Hepatitis B vaccine shortly after birth, because 
reduces the risk of getting the disease from mother or family members who 
may not know they are infected (WHO, 2008). The average values of vaccine 
coverage for the period 2012-2016 referring to this vaccine resulted to be 
always above 98%. 
 
Immunization coverage in childhood (5-6 year old children) 
Immunization coverage levels for vaccines applied to children at the 
age of 5- 6 are high and stable. This growing trend is perhaps related to the 
hypothesis that parents with under two year old children have different 
opinions compared to the six-year-old children parents. 
Imunization coverage for vaccines applied in adolescence (14 – 18 year old) 
In Korça district, for the year 2014, 2900 adults of the age 18 to 19 
were planned to receive the booster dose of tetanus/diphtheria (TT/Td4) 
vaccine; but in fact, only 87.8% of them were vaccinated. A slight increase of 
vaccine coverage level was observed in 2016 (Table 4), with an average value 
of 94.0%.  
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Vaccine  type                                                  
                              Year 
Td-3 TT / Td-4 
2012 98.8 -------- 
2013 99.3 -------- 
2014 96.7 87.8 
2015 95.6 93.2 
2016 97.7 94.0 
Average value (%) 97.6 91.7 
95% CI: 96.3- 98.9 87.8- 95.5 
 
Table 4: Vaccine coverage for vaccines applied in adolescence in  Korça 
district 
 
For this age, a greater attention is needed to improve the access to 
vaccination services. The immunization coverage values observed in 2016, 
showed a non-optimal continuity of these levels, especially when referring to 
the third dose of pentavalent vaccine which was calculated to have a 90.0%  
value. (Chart 2). 
 
 
Chart 2: The coverage for the vaccines considered in the study for the year 2016 in Korça district 
 
Conclusion 
During the three years period, 2012 to 2014, stable coverage values 
were estimated except those offered by measles vaccine, for which a decrease 
was reported in 2013, and for DTP-1 vaccine especially in 2014. 
Immunization coverage values for DTP vaccine for the period of years 2015-
2016 showed a visible increase for the first dose of Hepatitis B vaccine. As for 
the third dose of DTP-HepB-Hib vaccine, in the same period we noticed that 
the values of immunization coverage were decreasing.   
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Considering the data analyzed for the year 2016, we noticed a non-optimal 
continuity regarding to the fourth booster dose of TT/ Td vaccine and to the 
third dose of pentavalent vaccine, too (90.0%).  
A threat to the immunization program that needs to be considered in 
the future (Pojani, Ylli, 2016), remains the tendency towards an unreasonable 
concern about vaccinations and the global refusal, which is being noticed, in 
implementing them (Damnjanović et al, 2018), (Grzybowski et al 2017). 
According to the most recent WHO and UNICEF immunization data, nearly 
1 in 10 infants worldwide did not receive any vaccinations in 2016 (WHO, 
2017).   
In order to continue maintening high levels of vaccination coverage, 
the following steps are highly recommended: closely tracking and monitoring 
the vaccination calendar for all children in Albania, strengthenin the 
surveillance and working to eleminate the receptive pockets presented by still 
unvaccinated children due to parents’ negligence or refusal. 
Regarding the analysis of Korca regional immunization program in 2015 and 
2016, was observed and increase of about 25% of the number of vaccination 
rejection without a clinical reason. We recommend special attention be given 
to vaccination of children living in urban aereas and it is also important to 
supervise the preservation of protection levels for all age groups and 
geographical areas in Albania. 
The vaccination programme should ensure the equality of the coverage 
among the population. It should be noted that an effective vaccination 
programme must be accompanied by an effective surveillance of diseases to 
be controlled. 
 
References: 
1. Andre, FE., Booy, R., Bock, HL., Clemens, J., Datta, SK., John, TJ., 
Schmitt, HJ (2008). Vaccination greatly reduces disease, disability, 
death and inequity worldwide. Bulletin of the World Health 
Organization, 86(2), 140–146. doi:10.2471/blt.07.040089. 
2. Bhat, M., Ghali, P., Deschenes, M., & Wong, P. (2014). Prevention 
and Management of Chronic Hepatitis B. International journal of 
preventive medicine, 5 (Suppl 3), S200–S207. 
3. Chang, MH., & Chen, DS. (2015). Prevention of hepatitis B. Cold 
Spring Harbor perspectives in medicine, 5(3), a021493. 
doi:10.1101/cshperspect.a021493. 
4. Damnjanović, K., Graeber, J., Ilić, S., Lam, WY., Lep, Ž., Morales, S., 
Vingerhoets, L. (2018). Parental Decision-Making on Childhood 
Vaccination. Frontiers in psychology, 9,735. 
doi:10.3389/fpsyg.2018.00735. 
 
European Scientific Journal February 2020 edition Vol.16, No.6 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
63 
5. Delany, I., Rappuoli,R., De Gregorio, E. (2014). Vaccines for the 
21st century. EMBO Molecular Medicine. 6:708-720 
doi.org/10.1002/emmm.201403876.  
6. Greenwood, B. (2014). The contribution of vaccination to global 
health: past, present and future. Philosophical transactions of the Royal 
Society of London. Series B, Biological sciences, 369(1645), 
20130433. doi:10.1098/rstb.2013.0433. 
7. Grzybowski, A., Patryn, RK., Sak, J., & Zagaja, A. (2017). 
Vaccination refusal. Autonomy and permitted coercion. Pathogens and 
global health, 111(4), 200–205. 
8. Katz, DL., Wild, D., Elmore, JG., Lucan, SC. (2013). Jekel's 
Epidemiology, Biostatistics, Preventive Medicine, and Public Health. 
4th Edition. Saunders: 2013. 
9. Lahariya, Ch. (2015). Health system approach for improving 
immunization program performance. J. Family Med Prim Care, 4(4): 
487–494. 
10. Nabel, JG. (2013, February). Designing Tomorrow’s Vaccines. The 
New England Journal of Medicine. 368(6): 551–560. 
doi: 10.1056/NEJMra1204186. 
11. Orenstein, AW., Perry, RT., & Halsey, AN. (2004, May). The Clinical 
Significance of Measles: A Review. The Journal of Infectious 
Diseases. Volume 189, Issue Supplement_1,Pages S4–
S16, https://doi.org/10.1086/377712. 
12. Plotkin S. (2014). History of vaccination. Proceedings of the National 
Academy of Sciences of the United States of America, 111(34), 
12283–12287. doi:10.1073/pnas.1400472111. 
13. Pojani, E. (2017). Evaluation of the efficacy of vaccines used in 
Albania through the study of immune response in vaccinated subjects 
with combined (MMR) or monovalent (Hepatitis B) vaccines. Thesis. 
Tirana, Albania.  
14. Pojani, E., Nelaj, E. (2016). Health Effects of Diseases Protected by 
Combined Vaccines Used in Albania. Journal of Health Science 4: 8-
14.  
15. Pojani, E., Nelaj, E. & Ylli, A. (2017). An Insight into the 
Immunization Coverage for Combined Vaccines in Albania. European 
Scientific Journal. 13: 33-42. 
16. Pojani, E., Ylli, A. (2016). Vaccination Knowledge and Attitudes of 
Albanian Mothers. 10th International Congress on Social Sciences. 
Volume I. Madrid, Spain.  
17. Wallace, AS., Ryman, TK., & Dietz, V. (2014). Overview of global, 
regional, and national routine vaccination coverage trends and growth 
patterns from 1980 to 2009: implications for vaccine-preventable 
European Scientific Journal February 2020 edition Vol.16, No.6 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
64 
disease eradication and elimination initiatives. The Journal of 
infectious diseases, 210 Suppl 1(0 1), S514–S522. 
doi:10.1093/infdis/jiu108. 
18. World Health Organization (2013). Vaccine Safety Basics. Learning 
Manual. 
19. World Health Organization (2019). Recent Immunization Data. 
Retrieved 
from:http://www.who.int/immunization/monitoring_surveillance/en. 
20. World Health Organization (2018, June). World Health Organization 
Vaccination Coverage Cluster Surveys: Reference Manual. Version 3. 
WHO/IVB/18.09. 
21. World Health Organization, UNICEF, World Bank. (2009). State of 
the world’s vaccines and immunization. 3rd ed. Geneva, Switzerland: 
Available 
from:http://apps.who.int/iris/bitstream/10665/63027/1/WHO_GPV_9
6.04.pdf. 
22. World Health Organization (2008). Hepatitis B: Factsheet No. 204. 
Retrieved from:    
http://www.who.int/ mediacentre/ factsheets/ fs204/ en/.doi:10.1080/
20477724.2017.1322261. 
23. World Health Organization (2017). 1 in 10 infants worldwide did not 
receive any vaccinations in 2016. Retrieved from:  
http://www.who.int/mediacentre/news/releases/2017/infants-
worldwide-vaccinations/en. 
 
 
 
 
 
 
 
 
 
 
 
 
